ZYXIQ Shareholders Race April 21 Deadline to Claim Fraud Lawsuit Recovery Chances

The immediate investment question for Zynex is now stark. The old equity is a zero-value instrument. The company's bankruptcy confirmation on March 19, 2026, canceled all existing shares, leaving the stock (ZYXIQ) as a speculative claim against a legal process. The catalyst that defines its potential recovery is a securities class action lawsuit, with a hard deadline looming.

The lawsuit, filed in early March, alleges a systematic fraud. It claims that from February 25, 2021 to December 15, 2025, Zynex executives engaged in a "fraudulent overbilling scheme" by systematically "oversupplying" medical electrodes to patients regardless of medical necessity. This practice, the complaint alleges, was used to inflate billings to government and private payors and artificially boost reported revenue. The core allegation is that the company's growth was not driven by legitimate demand but by illegal overbilling.

This is the event that must be priced. The lawsuit seeks to recover losses for investors who bought stock during that period. The critical date is April 21, 2026. That is the deadline for shareholders with losses to formally register and seek appointment as lead plaintiff. Missing it forfeits the right to be a lead plaintiff, though it does not bar participation in any eventual recovery.

The setup is clear. The bankruptcy has wiped out the old equity. The lawsuit is the only remaining asset that could generate a recovery. The April 21 deadline is the near-term event that will determine who gets to shape the legal fight and, potentially, the size of any payout. For now, the stock is a claim, not a company.

The Mechanics of the Event: Fraud Allegations and Regulatory Penalties

The lawsuit's allegations are not abstract. They describe a specific, systematic fraud that directly ties to the company's financial collapse. The core claim is an "oversupplying scheme" where executives routinely shipped patients up to 128 electrode pairs per month, far beyond any medical necessity. This wasn't isolated billing errors; it was a deliberate practice to inflate billings to government and private payors, including Tricare, which represented a quarter of Zynex's revenue. The fraud was operational, not just accounting.

The regulatory fallout has been severe and concurrent. In March 2025, Tricare suspended payments, leading to a $85 million forfeiture to resolve the allegations. Then, in January 2026, the criminal hammer fell: the former CEO and COO were indicted for health care and securities fraud, resulting in their immediate removal. These actions are not separate from the securities lawsuit; they are the factual foundation that validates the fraud claims and demonstrates the scale of the misconduct.

This is where the mechanics of the bankruptcy plan create a critical, near-total wipeout for former shareholders. The Ad Hoc Group of Bondholders and DIP Lenders will receive all new equity in the reorganized company via a credit bid of their $22 million financing. The plan confirms this transfer, with roughly 1,000 new common shares issued solely to the plan sponsor, an entity owned by these lenders. In effect, the creditors who funded the company through its final days are being given the entire new ownership stake.

The bottom line is stark. The securities lawsuit seeks to recover losses from a fraud that is now legally established. Yet the bankruptcy plan ensures that the equity that could theoretically be used to fund any recovery is not available to former shareholders. It is being transferred to the very creditors who are now the new owners. For the old equity holders, the lawsuit is the only remaining path to a potential payout, but it is a path with no equity stake to back it. The fraud allegations are real and damaging, but the legal structure of the recovery has already decided who gets the company-and it is not the former stockholders.

The Immediate Risk/Reward Setup

The trading status of ZYXIQ is now a pure speculation play. The company itself has warned that the bankruptcy process will result in a "significant loss" for existing equity holders. With the old shares canceled and the new entity's equity transferred to the DIP lenders, the stock is a claim against a legal process, not a stake in an operating business. This creates a high-risk, high-volatility setup where price moves are driven entirely by litigation milestones, not operational performance.

The primary near-term catalyst is the April 21, 2026 deadline for the securities class action lawsuit. This is the event that could yield a recovery for investors who bought during the fraud period. The lawsuit, filed in early March, alleges a systematic "oversupplying scheme" that inflated revenue. For those who qualify, the lead plaintiff appointment is a critical step to potentially shape the case and influence any settlement or judgment. Missing this deadline means losing the right to be a lead plaintiff, though it does not bar a claim for a recovery.

The critical point is that the new entity's value is tied to the successful execution of the bankruptcy plan and the resolution of ongoing litigation, not the old stock. The plan's confirmation ensures the new equity goes to the lenders who funded the reorganization. Any recovery for former shareholders must come from the lawsuit against the former executives and the company's assets, which are now largely depleted by regulatory penalties and the fraud itself. The risk/reward here is binary: the lawsuit either succeeds in generating a meaningful payout, or the stock remains a worthless claim. For now, the setup is defined by a single, hard deadline.